Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Idalopirdine in Renal Impairment
NCT02340195Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jan 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Idalopirdine in Alzheimer's disease (AD) (4 arms), sponsored by Lundbeck. Primary endpoints: Area under the plasma concentration-time curve from time zero to 24 hours and Maximum observed plasma concentration at Day 10. Started Jan 2015; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02340195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340195.